AstraZeneca Reports Results of Farxiga (dapagliflozin) in P-III DAPA-HF Study to Treat Patients with Heart Failure

 AstraZeneca Reports Results of Farxiga (dapagliflozin) in P-III DAPA-HF Study to Treat Patients with Heart Failure

AstraZeneca Reports Results of Farxiga (dapagliflozin) in P-III DAPA-HF Study to Treat Patients with Heart Failure

Shots:

  • The P-III DAPA-HF study involves assessing of Farxiga (10mg, qd) vs PBO in patients with heart failure and reduced ejection fraction (HFrEF) (LVEF ≤ 40%), with/without type-2 diabetes on the addition to SOC including ACE inhibitors, ARB, MRAs, beta-blockers and neprilysin inhibitors
  • The P-III DAPA-HF study resulted in meeting its 1EPs i.e, reduction in cardiovascular death or worsening of heart failure
  • Farxiga is an oral SGLT2 inhibitor, indicated as both monothx. and combination therapy to improve glycemic control, reduction in weight & blood pressure as an adjunct to diet and exercise in patients with T2D, also being studied in patients with HF in DELIVER and DETERMINE (HFrEF and HFpEF) trials respectively

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: Inquirer

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post